Abstract
The support statement for Lepor NE et al, “The potential role of anti-PCSK9 monoclonal antibodies in the management of hypercholesterolemia,” Rev Cardiovasc Med. 2014;15(4):290-309, was incorrectly attributed. This activity is supported by an educational grant from sanofi-aventis U.S. and Regeneron Pharmaceuticals. The corrected article appears overleaf with its original pagination.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
